AstraZeneca PLC
LSE:AZN
AstraZeneca PLC
Gross Profit
AstraZeneca PLC
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
AstraZeneca PLC
LSE:AZN
|
Gross Profit
$45.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
18%
|
CAGR 10-Years
8%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Gross Profit
£22.6B
|
CAGR 3-Years
11%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
4%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Gross Profit
$39.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Indivior PLC
LSE:INDV
|
Gross Profit
$1.7B
|
CAGR 3-Years
36%
|
CAGR 5-Years
24%
|
CAGR 10-Years
6%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Gross Profit
$1.4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
5%
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Gross Profit
£109.3m
|
CAGR 3-Years
0%
|
CAGR 5-Years
5%
|
CAGR 10-Years
16%
|
|
AstraZeneca PLC
Glance View
AstraZeneca PLC stands as a formidable entity in the global pharmaceutical landscape, adeptly navigating the intricate dance of innovation and commerce. Emerging from a merger between Sweden's Astra AB and the UK's Zeneca Group in 1999, the company has carved a niche through its relentless pursuit of cutting-edge medical solutions. Central to its operations is a sophisticated ecosystem of research and development, where thousands of scientists tirelessly explore the expansive frontier of biotechnology. The lifeblood of AstraZeneca's growth is its robust pipeline, where potential life-saving medicines traverse an arduous journey from laboratory benches to clinical trials, and eventually, regulatory approval. This rigorous process underscores its commitment to addressing complex diseases in areas such as oncology, cardiovascular, and respiratory health – domains marked by high unmet medical needs and significant market demand. The commercial prowess of AstraZeneca is equally vital to its success narrative. With a global reach spanning over 100 countries, the company leverages its advanced production facilities and strategic partnerships to deliver its pharmaceutical breakthroughs to those in need. Revenue generation is predominantly through the sale of prescription drugs, with blockbuster medications serving as pivotal financial pillars. These products, once approved, are strategically marketed to healthcare providers, ensuring they gain traction in various markets. AstraZeneca's approach is finely tuned to balance the scale of mass production with the nuance of catering to specific regional demands, maintaining a competitive edge in a crowded pharmaceutical landscape. Through these intricacies of innovation, production, and strategic market positioning, AstraZeneca not only generates substantial revenues but also reinforces its mission to improve patient health outcomes worldwide.
See Also
What is AstraZeneca PLC's Gross Profit?
Gross Profit
45.3B
USD
Based on the financial report for Mar 31, 2025, AstraZeneca PLC's Gross Profit amounts to 45.3B USD.
What is AstraZeneca PLC's Gross Profit growth rate?
Gross Profit CAGR 10Y
8%
Over the last year, the Gross Profit growth was 16%. The average annual Gross Profit growth rates for AstraZeneca PLC have been 15% over the past three years , 18% over the past five years , and 8% over the past ten years .
You don't have any saved screeners yet